Literature DB >> 1282967

Endothelium-dependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension.

S Taddei1, A Virdis, P Mattei, F Arzilli, A Salvetti.   

Abstract

Endothelium-dependent vasodilation is reduced in essential hypertensive subjects. To evaluate whether this abnormality is a primary defect or is a consequence of blood pressure increment, in offspring of essential hypertensive and normotensive subjects (n = 13 subjects for each group) matched for age, sex, body weight, and blood pressure, we studied the response of forearm vasculature to acetylcholine (ACh) (an endothelium-dependent vasodilator), sodium nitroprusside (a direct vasodilator of vascular smooth muscle), and forearm ischemia (13 min plus 1 min of exercise) to induce maximal vasodilation. Drugs were infused into the brachial artery at cumulative doses (ACh: 0.15, 0.45, 1.5, 4.5, and 15 micrograms/100 ml of forearm tissue/min; sodium nitroprusside: 1, 3, and 10 micrograms/100 ml of forearm tissue/min) while forearm blood flow was measured by strain-gauge venous plethysmography. The intra-arterial blood pressure and heart rate were continuously monitored. Despite a comparable forearm vascular response to sodium nitroprusside and to forearm ischemia, the effect of ACh was significantly (p < 0.001) reduced in offspring of hypertensive subjects compared to the offspring of normotensive subjects. These data indicate that ACh-mediated forearm vasodilation is reduced in normotensive subjects with a familial history of essential hypertension, a finding that suggests that endothelium dysfunction can precede the appearance of hypertension and that this abnormality might play a role in the pathogenesis of essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1282967     DOI: 10.1097/00005344-199204002-00054

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  20 in total

1.  Quality of life in patients with silent atrial fibrillation.

Authors:  I Savelieva; M Paquette; P Dorian; B Lüderitz; A J Camm
Journal:  Heart       Date:  2001-02       Impact factor: 5.994

Review 2.  Endothelial dysfunction and hypertension.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 3.  Cardioprotective mechanisms of ACE inhibition. The angiotensin II-nitric oxide balance.

Authors:  G H Gibbons
Journal:  Drugs       Date:  1997       Impact factor: 9.546

4.  Endothelial dysfunction in hypertensive patients and in normotensive offspring of subjects with essential hypertension.

Authors:  B Zizek; P Poredos; V Videcnik
Journal:  Heart       Date:  2001-02       Impact factor: 5.994

Review 5.  Human endothelial dysfunction: EDRFs.

Authors:  Andreas J Flammer; Thomas F Lüscher
Journal:  Pflugers Arch       Date:  2010-04-12       Impact factor: 3.657

6.  Effect of 1-week treatment with erythropoietin on the vascular endothelial function in anaesthetized rabbits.

Authors:  K Noguchi; S Yamashiro; T Matsuzaki; M Sakanashi; J Nakasone; K Miyagi; M Sakanashi
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

7.  Novel risk factors in long-term hypertension incidence in type 1 diabetes mellitus.

Authors:  Karine Sahakyan; Barbara E K Klein; Chelsea E Myers; Michael Y Tsai; Ronald Klein
Journal:  Am Heart J       Date:  2010-06       Impact factor: 4.749

Review 8.  Angiotensin II and nitric oxide interaction.

Authors:  Marc de Gasparo
Journal:  Heart Fail Rev       Date:  2002-10       Impact factor: 4.214

9.  Protein restriction during pregnancy induces hypertension and impairs endothelium-dependent vascular function in adult female offspring.

Authors:  Kunju Sathishkumar; Rebekah Elkins; Uma Yallampalli; Chandra Yallampalli
Journal:  J Vasc Res       Date:  2008-10-29       Impact factor: 1.934

10.  Association of urinary N-domain Angiotensin I-converting enzyme with plasma inflammatory markers and endothelial function.

Authors:  Fernanda B Fernandes; Frida L Plavnik; Andressa Ms Teixeira; Dejaldo Mj Christofalo; Sergio A Ajzen; Elisa Ms Higa; Fernanda A Ronchi; Ricardo Cc Sesso; Dulce E Casarini
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.